Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00725400 | Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma | withdrawn | Phase 2 | 450 | American Scitech InternationalOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | withdrawn | Phase 2 | 37 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00577668 | A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00162513 | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | — | Hadassah Medical OrganizationOTHER | 1 | Apr 28, 2011 | clinicaltrials |
| NCT00149032 | Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host | withdrawn | Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Apr 8, 2011 | clinicaltrials |
| NCT01170052 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | withdrawn | Phase 1 / Phase 2 | 20 | Charite University, Berlin, GermanyOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT00233636 | Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 28 | AstraZenecaINDUSTRY | 1 | Jan 27, 2011 | clinicaltrials |
| NCT00162500 | A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies | withdrawn | Phase 2 | 15 | Hadassah Medical OrganizationOTHER | 1 | Nov 10, 2010 | clinicaltrials |
| NCT00298467 | MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma | withdrawn | Phase 2 | 45 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 26, 2010 | clinicaltrials |
| NCT00243490 | Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors | withdrawn | Phase 2 | 5 | National Taiwan University HospitalOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00712621 | Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination | withdrawn | Phase 2 | 460 | American Scitech InternationalOTHER | 1 | Nov 24, 2009 | clinicaltrials |
| NCT00963664 | Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma | withdrawn | Phase 2 | 250 | NeoPlas InnovationOTHER | 1 | Sep 9, 2009 | clinicaltrials |
| NCT00485966 | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 25 | Cylene PharmaceuticalsINDUSTRY | 1 | Nov 5, 2008 | clinicaltrials |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 2 | 20 | University of CincinnatiOTHER | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00172367 | Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma | withdrawn | Phase 2 | 80 | National Taiwan University HospitalOTHER | 1 | Sep 26, 2008 | clinicaltrials |
| NCT00676871 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 / Phase 2 | 30 | MedImmune LLCINDUSTRY | 0 | Sep 5, 2008 | clinicaltrials |
| NCT00415155 | A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 29, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Jul 20, 2011source: clinicaltrials